Press Releases

OriGene Technologies and Nanoportal Biotech Join Forces to Bring Groundbreaking ProteanFect™ Gene Delivery Technology to Researchers Worldwide

November 10, 2025 - Rockville, Maryland, USA - OriGene Technologies, a global leader in gene-centric research tools, today announced an exclusive distributorship and a co-marketing partnership with Nanoportal Biotech for ProteanFect™, an industry-first, coacervate-based gene delivery reagent that promises to redefine transfection in challenging cell types.

(Read Full Press Release)

HistoWiz Validates OriGene's IHC Antibodies for 9 Key Pathology Targets

August 11, 2025 - Rockville, Maryland, USA - OriGene and HistoWiz announced a new collaboration to integrate OriGene's antibodies into HistoWiz's PathologyMap™ platform. This partnership aims to streamline the histopathology workflow for researchers by providing direct access to validated reagents and interactive, high-resolution images of antibody performance.

(Read Full Press Release in Pathology News)

OriGene Technologies has been Selected as the 2023 Bioz Stars Award Winner in Various Product Categories

January 29th, 2023 - Rockville, Maryland, USA - OriGene is excited to announce that it has been selected as the 2023 Bioz Stars Award Winner in the following categories: Cloning, Vectors, & CRISPR. In the cloning.

( Full Press Release Full Press Release )

OriGene Technologies Updates Logo for Rebranding Its Expansion from Genomics to Proteomics OriGene Technologies Updates Logo for Rebranding Its Expansion from Genomics to Proteomics

Jan 7th, 2022 - Rockville, Maryland, USA - OriGene updates its logo, signifying its evolvement from genomic to proteomic market. The logo modification includes an addition of antibody/antigen image to the previous logo.

( Full Press Release Full Press Release )

OriGene Technologies and EdiGene Announce Joint Development of Genome Wide Knockout Cell Lysates OriGene Technologies and EdiGene Announce Joint Development of Genome Wide Knockout Cell Lysates

November 21, 2016 - Rockville, Maryland, USA - OriGene Technologies, a large supplier of genecentric research tools, today announced that it has entered into a multi-year strategic agreement with EdiGene (Beijing, China) to develop genome wide knockout cells from commonly used laboratory cell lines.

( Full Press Release Full Press Release )

ALK UltraMAB® Antibody (OTI1A4) Outperform D5F3 Antibody, Successfully Demonstrating Higher Sensitivity in NSCLC Immunohistochemistry Diagnostics ALK UltraMAB® Antibody (OTI1A4) Outperform D5F3 Antibody, Successfully Demonstrating Higher Sensitivity in NSCLC Immunohistochemistry Diagnostics

April 14, 2016 - Rockville, Maryland, USA - A pair of recently published studies shed light on the highly interesting area on detection of ALK expression among NSCLC patients by IHC. One study was conducted by NordiQC (Aalborg, Denmark).

( Full Press Release Full Press Release )

OriGene & Dako Establish Multi-year Antibody Development Collaboration and Announce Commercial License Grant for “Ultra-Specific” Monoclonal Antibody for ALK Detection OriGene & Dako Establish Multi-year Antibody Development Collaboration and Announce Commercial License Grant for “Ultra-Specific” Monoclonal Antibody for ALK Detection

April 14, 2016 - Rockville, Maryland, USA - OriGene Technologies, Inc., announced today that it has entered into a multi-year antibody development collaboration featuring its proprietary UltraMAB® technology platform and granted to Dako, an Agilent Technologies company (Santa Clara, CA), a worldwide non-exclusive commercial license to OriGene’s mouse anti-ALK monoclonal antibody clone OTI1A4 for research and diagnostics use within the immunocytochemistry and immunohistochemistry fields.

( Full Press Release Full Press Release )

OriGene Technologies Awarded Phase II SBIR Contract to Develop High-Affinity, Anti-Peptide Monoclonal Antibodies for SISCAPA Assays OriGene Technologies Awarded Phase II SBIR Contract to Develop High-Affinity, Anti-Peptide Monoclonal Antibodies for SISCAPA Assays

Rockville, MD – January 7th, 2016 - OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.

( Full Press Release Full Press Release )

OriGene Technologies Strengthens Antibody Portfolio by Acquiring Acris Antibodies GmbH OriGene Technologies Strengthens Antibody Portfolio by Acquiring Acris Antibodies GmbH

Rockville, MD – Oct 28, 2015 – OriGene Technologies, Inc. (“OriGene”), an industry leader of genome wide products for research and diagnostic applications, announced today that it has acquired Acris Antibodies GmbH (“Acris Antibodies”), a provider of antibodies and other life science related products.

( Full Press Release Full Press Release )

SDIX, LLC, an OriGene Company, Achieves Significant Milestone with ISO 13485:2003 Certification SDIX, LLC, an OriGene Company, Achieves Significant Milestone with ISO 13485:2003 Certification

Newark, DE– Oct 28, 2015 – OriGene Technologies, Inc. (“OriGene”), an industry leader of genome wide products for research and diagnostic applications, announced today that it has acquired Acris Antibodies GmbH (“Acris Antibodies”), a provider of antibodies and other life science related products.

( Full Press Release Full Press Release )

OriGene Technologies Acquires BioCheck OriGene Technologies Acquires BioCheck

Rockville, MD– Feb 26, 2014 – OriGene Technologies, Inc. (“OriGene”),one of the industry leaders in producing genome wide products for research and diagnostic applications, announced today that it has acquired BioCheck, Inc, a provider of innovative immunodiagnostic test kits and custom immunoassay development for the world-wide health care and research markets.

( Full Press Release Full Press Release )

OriGene Technologies awarded NCI contract to develop high affinity anti-peptide antibodies for SISCAPA SRM assays in partnership with the Institute for Systems Biology OriGene Technologies awarded NCI contract to develop high affinity anti-peptide antibodies for SISCAPA SRM assays in partnership with the Institute for Systems Biology

Rockville, MD– Jan 30, 2014 – OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has been awarded a contract from the National Cancer Institute (NCI) to develop high affinity anti-peptide antibodies for SISCAPA assays.

( Full Press Release Full Press Release )